207 related articles for article (PubMed ID: 12566909)
1. Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
Aihara T; Takatsuka Y; Itoh K; Sasaki Y; Katsumata N; Watanabe T; Noguchi S; Horikoshi N; Tabei T; Sonoo H; Hiraki S; Inaji H
Oncology; 2003; 64(2):124-30. PubMed ID: 12566909
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Khayat D; Chollet P; Antoine EC; Monfardini S; Ambrosini G; Benhammouda A; Mazen MF; Sorio R; Borg-Olivier O; Riva A; Ramazeilles C; Azli N
J Clin Oncol; 2001 Jul; 19(14):3367-75. PubMed ID: 11454884
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Nabholtz JM; Falkson C; Campos D; Szanto J; Martin M; Chan S; Pienkowski T; Zaluski J; Pinter T; Krzakowski M; Vorobiof D; Leonard R; Kennedy I; Azli N; Murawsky M; Riva A; Pouillart P;
J Clin Oncol; 2003 Mar; 21(6):968-75. PubMed ID: 12637459
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
Sparano JA; O'Neill A; Schaefer PL; Falkson CI; Wood WC
J Clin Oncol; 2000 Jun; 18(12):2369-77. PubMed ID: 10856096
[TBL] [Abstract][Full Text] [Related]
6. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer.
Palmeri S; Leonardi V; Tamburo De Bella M; Morabito A; Vaglica M; Accurso V; Ferraù F; Failla G; Agostara B; Massidda B; Valenza R; Fanelli M; Gasparini G
Oncology; 2002; 63(3):205-12. PubMed ID: 12381898
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.
Muthalib A; Darwis I; Prayogo N; Sutjipto
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():498-504. PubMed ID: 10895201
[TBL] [Abstract][Full Text] [Related]
11. Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.
Alba E; Ribelles N; Antón A; Pérez-Carrión R; López-Vega JM; Llanos M; Pelegri A; Florián J; Menéndez M; Godes MJ;
Breast Cancer Res Treat; 2003 Jan; 77(1):1-8. PubMed ID: 12602899
[TBL] [Abstract][Full Text] [Related]
12. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
14. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
Mavroudis D; Alexopoulos A; Malamos N; Ardavanis A; Kandylis C; Stavrinidis E; Kouroussis Ch; Agelaki S; Androulakis N; Bozionelou V; Georgoulias V
Oncology; 2003; 64(3):207-12. PubMed ID: 12697959
[TBL] [Abstract][Full Text] [Related]
15. Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Diéras V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):31-3. PubMed ID: 9364539
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Nabholtz JM; Mackey JR; Smylie M; Paterson A; Noël DR; Al-Tweigeri T; Tonkin K; North S; Azli N; Riva A
J Clin Oncol; 2001 Jan; 19(2):314-21. PubMed ID: 11208821
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57.
Smith RE; Anderson SJ; Lembersky BC; Brown A; Mamounas E
Clin Breast Cancer; 2004 Aug; 5(3):208-15. PubMed ID: 15335453
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Kouroussis C; Androulakis N; Kakolyris S; Souglakos J; Kotsakis T; Mavroudis D; Katsogridakis K; Vardakis N; Hatzidaki D; Samonis G; Vlachonikolis J; Georgoulias V
J Clin Oncol; 1999 Mar; 17(3):862-9. PubMed ID: 10071277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
